Effect of a single continuing medical education (CME) report on prescription behaviour. Results from the disease management programme (DMP) coronary artery disease (CAD) in the North Rhine region, Germany

B. Hagen, I. Schwang, L. Altenhofen, R. Griebenow, J. Kretschmann & A. Weber
Background: In 2005 29.3% of the patients with heart failure (NYHA class 2–3) in the DMP CAD received a calcium antagonist (CAA), which is not part of the guideline recommended first line therapy (beta blockers BB plus ACE inhibitors ACE-I). Objective: Can a single CME report on use of[for full text, please go to the a.m. URL]